Quality of care for older adults with chronic obstructive pulmonary disease and asthma based on comparisons to practice guidelines and smoking status by Craig, Benjamin M et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Health Services Research
Open Access Research article
Quality of care for older adults with chronic obstructive pulmonary 
disease and asthma based on comparisons to practice guidelines 
and smoking status
Benjamin M Craig*1, Connie K Kraus2, Betty A Chewning3 and 
James E Davis4
Address: 1Health Outcomes & Behavior Program, Moffitt Cancer Center, Tampa, Florida, USA. Department of Economics, University of South 
Florida, Tampa, Florida, USA, 2School of Pharmacy and Department of Family Medicine, University of Wisconsin, Madison, Wisconsin, USA, 
3School of Pharmacy, University of Wisconsin, Madison, Wisconsin, USA and 4Department of Family Medicine, University of Wisconsin, Madison, 
Wisconsin, USA
Email: Benjamin M Craig* - benjamin.craig@moffitt.org; Connie K Kraus - ckkraus@pharmacy.wisc.edu; 
Betty A Chewning - bachewning@pharmacy.wisc.edu; James E Davis - Jim.Davis@fammed.wisc.edu
* Corresponding author    
Abstract
Background: The purpose of this study was to describe the prevalence of respiratory diseases in
older adults and compare the demographic, health and smoking characteristics of those with and
without these diseases. Furthermore, we evaluate the association between smoking status and
patterns in health care and how concordant this care is with guidelines.
Methods: Using a nationally representative sample of 29,902 older adults who participated in the
Medicare Current Beneficiary Survey (1992–2002), we compared guideline recommendations on
the treatment and prevention of chronic obstructive pulmonary disease and asthma with survey
utilization data, including the use of bronchodilators, spirometry and influenza vaccine.
Results: 26% to 30% of older adults were diagnosed with or self-reported chronic respiratory
diseases; however 69% received no pharmacological treatment and 30% of patients reporting use
of pharmacological treatments did not receive short-acting bronchodilator inhalers. Current
smokers appeared to receive significantly less care for respiratory diseases than non-smokers or
former smokers.
Conclusion: Disparities between recommended and actual care for older adults with chronic lung
disease require further research. The needs of older adults with co-morbidities and nicotine
addiction deserve special attention in care as well as guideline development and implementation.
Background
Chronic obstructive pulmonary disease (COPD) is the
fourth leading cause of death of adults in the world and a
leading cause of death in people over the age of 45 in the
United States [1]. The worldwide prevalence in 1990 was
estimated to be 9.34/1,000 in men and 7.33/1,000 in
women, but these estimates included all ages and may
have underestimated the true prevalence in older adults.
COPD causes a major financial burden to the healthcare
system [2]. Under-diagnosis and under-treatment are
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associated with increased use of emergency department
services due to exacerbations of the disease [3]. Imple-
mentation of practice guidelines, optimization of phar-
macotherapy and reduction of risk factors, like smoking,
have been shown to improve clinical and economic out-
comes.
Likewise, asthma mortality continues to increase in the
United States [4]. An analysis of asthma mortality
between 1979 and 1996 showed that people over age 65
have the highest crude mortality rates from asthma. Simi-
lar to COPD, asthma is often under-diagnosed and under-
treated in the elderly [5].
Practice guidelines for COPD and asthma have been avail-
able for a number of years [1,6-8]. Guidelines for the care
of both COPD and asthma emphasize the importance of
spirometry as an essential tool for the diagnosis and stag-
ing of severity [1,6,8]. Access to short-acting inhaled bron-
chodilators is recommended for persons with COPD and
asthma across the spectrum of disease severity. Yet, evi-
dence suggests that many patients do not receive recom-
mended care [6,8]. Preventive interventions, such as
immunizations and smoking cessation, are also promoted
for this population. Tobacco use is recognized as a major
risk factor for the development of COPD, and smoking
cessation is acknowledged as a means to prevent disease
progression [1,6]. Smoking also plays a role in exacerbat-
ing asthma [7,8]. Yet, smoking remains a common behav-
ior among older adults with COPD and/or asthma [1,6-
8].
The 1992–2002 Medicare Current Beneficiary Survey
(MCBS) is the only nationally representative survey over
this period that focused on the health and health care of
older adults. Using this dataset, our aims are to determine
the prevalence of COPD or asthma among older commu-
nity-dwelling adults in the United States and their demo-
graphic, treatment and smoking characteristics. We will
measure whether older adults with COPD or asthma
receive any pharmacotherapy, and test the association
between its delivery, medication type, and corresponding
care. Furthermore, we will evaluate the quality of their
care compared to guideline recommendations, with spe-
cial attention to older adults who smoke.
Methods
The Medicare Current Beneficiary Survey (MCBS) is
unique in several respects. Most importantly, it is a contin-
uous, panel survey of a nationally representative sample
of the Medicare population. The survey applies overlap-
ping cohort design and involves the over-sampling of
those over age 85 [9]. In complement to the collection of
survey data by face-to-face interviews over a four year
period, Centers for Medicare & Medicaid Services (CMS)
link the survey data to Medicare claims data over the sur-
vey years and all subsequent years. As of August 2005,
CMS has released 1991 through 2003 survey data on
76,880 beneficiaries including 222,545 person-years of
survey data and 254,554 person-years of claims data. Data
from the Access to Care and Cost & Use components of the
MCBS for the years 1991–2002 were combined and exam-
ined to improve understanding of access to and use of
health care among older adults with COPD or asthma.
The CMS employed computer-assisted personal inter-
viewing (CAPI) technology to collect survey data and ref-
erenced previous responses and claims to improve the
accuracy of the survey data. Respondents were given con-
tainers to collect prescription receipts and medication bot-
tles to assist respondent memory about prescribed
medicine events. Interviews occurred in person three
times per year, and respondents had to recall health care
related events that occurred up to approximately four
months before the interview. Response rates are 85% or
more for initial community interviews; participation in
subsequent rounds is 95% or more.
For this study, the sample selection criteria included that
a respondent: (1) was surveyed between 1992–2002; (2)
resided in the community setting in the continental U.S.,
Alaska or Hawaii; (3) survived the entire calendar year; (4)
enrolled in Medicare Parts A and B for the entire year; (5)
was age 67 years by December 31st of the survey year; and
(6) had no participation in Medicare Plus Choice. CMS
does not have claims data for the current or previous year
for those beneficiaries who are younger than age 67, are
not enrolled in Parts A and B, or participated in Medicare
plus Choice; hence they were removed from the sample.
The analytical sample for this analysis contains data on
29,202 respondents including 73,386 person-years of sur-
vey data since patients have multiple years in the sample.
Using the survey data, we analyzed patient demographic
and socioeconomic data, as well as use of prescription
medicines. Other than medication use, the survey varia-
bles represent fall survey responses. For example, smoking
status represents point-in-time coverage during the fall
interview of the survey year. Chi-squared and t-tests were
applied to test the statistical significance of differences in
respondent characteristics and delivery of health care by
the presence of obstructive respiratory disease and phar-
macotherapy (Tables 1 and 2, respectively).
Diagnosis of COPD and asthma was measured using the
presence of ICD-9 diagnostic codes on inpatient, outpa-
tient, skilled nursing facility, hospice, home health
agency, durable medical equipment, or physician claims,
and through a survey question. For each survey year of
data, the survey year's claims and previous year's claimsBMC Health Services Research 2008, 8:144 http://www.biomedcentral.com/1472-6963/8/144
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were reviewed to identify respondents with a clinical diag-
nosis of COPD or asthma. These codes included COPD
(chronic bronchitis–ICD-9 codes 490–491, emphy-
sema–ICD-9 code 492, bronchiectasis–ICD-9 code 494,
chronic airway obstruction–ICD-9 code 496) and asthma
(ICD-9 code 493) [10]. In addition to clinical diagnoses
through claims data, respondents were asked, "Has a doc-
tor ever told you that you had emphysema, asthma, or
COPD?" as a form of self-reported indication. Similar
questions were asked about hypertension, heart condi-
tions, stroke, cancer, diabetes, arthritis and osteoporosis,
and these self-reported indications were aggregated to
count an individual's chronic comorbidities. For example,
the cancer indicator represents an affirmative response to
the question, "Has a doctor ever told you that you had any
kind of cancer, malignancy, or tumor other than skin can-
cer?"
The utilization of Medicare-covered health care services
was measured using information taken from the claims
Table 1: Characteristics of Older Adults With and Without Obstructive Respiratory Disease, 1992–2002
Characteristics No Obstructive 
Respiratory Disease
Obstructive 
Respiratory Disease
p-value
Number of person-years 51861 21525
Female, % 0.61 0.56 <0.01
Race, %
White 0.88 0.89 0.73
Black 0.09 0.08 <0.01
Other 0.03 0.03 <0.01
Hispanic, % 0.04 0.04 <0.01
Income less than $25,000, % 0.66 0.72 <0.01
Education, %
Less than High School 0.22 0.26 <0.01
High School 0.48 0.49 0.04
More than High School 0.29 0.24 <0.01
Drug Coverage, %
None 0.47 0.42 <0.01
Medicaid 0.08 0.13 <0.01
Employer 0.32 0.31 0.28
Individual 0.09 0.09 0.99
Other Public 0.05 0.06 <0.01
Regional Characteristics, %
Resides in MSA 0.60 0.60 0.6
Resides in Northeast 0.20 0.19 <0.01
Resides in Midwest 0.27 0.23 <0.01
Resides in South 0.39 0.42 <0.01
Resides in West 0.14 0.16 <0.01
Number of Chronic Conditions 1.14 1.36 <0.01
Chronic Conditions, %
Hypertension 0.56 0.61 <0.01
Heart Condition 0.02 0.04 <0.01
Stroke 0.11 0.14 <0.01
Cancer 0.18 0.22 <0.01
Diabetes 0.16 0.18 <0.01
Arthritis 0.09 0.13 <0.01
Osteoporosis 0.01 0.02 <0.01
Fair or Poor Health Status, % 0.19 0.34 <0.01
Limitations in Activities of Daily Living, %
No Limitations 0.73 0.61 <0.01
1 or 2 limitations 0.18 0.25 <0.01
3 or 4 limitations 0.06 0.09 <0.01
5 or 6 limitations 0.03 0.04 <0.01
Some or more difficulty walking 2 or 3 blocks or 1/4 mile 0.32 0.50 <0.01
Smoking History %
None 0.47 0.31 <0.01
Former Smoker, % 0.45 0.53 <0.01
Current Smoker, % 0.08 0.16 <0.01BMC Health Services Research 2008, 8:144 http://www.biomedcentral.com/1472-6963/8/144
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data. Specifically, we identified (a) whether the respond-
ent had any visits with a pulmonologist based on the pres-
ence of physician claims with specialty code 29; (b) any
spirometry procedures based on the presence of physician
or outpatient claims with Healthcare Common Procedure
Code (HCPC) 94010, 94060, and 94375; and (c) any
community-setting oxygen use based on durable medical
equipment events during the survey year. Influenza vacci-
nation for the previous winter was measured by self-
report.
The utilization of outpatient prescription medications
was measured based on survey information on prescribed
medicine events. The prescribed medicine events were cat-
egorized using drug names and translated into the World
Health Organization Anatomical Therapeutic Chemical
(ATC) classification system [11]. We examined the preva-
lence of prescribed medicine events for all drugs for
obstructive airway diseases (R03) including: corticoster-
oid inhalers (R03BA), xanthines (R03DA), selective beta-
2 adrenoreceptor agonist inhalers (R03AC), leukotriene
receptor antagonists (R03DC) and anticholinergic inhal-
ers (R03BB). Over the period 1992–2002, anticholiner-
gics agents included ipratropium and the combination of
ipratropium with albuterol (Combivent®). Tiopropium
(Spiriva®) was not available during this time.
Since guidelines for asthma and COPD recommended
access to a short-acting inhaled bronchodilator for all
patients with asthma and for symptomatic (mild-severe)
patients with COPD, evidence of access to a short-acting
inhaled bronchodilator was used as a surrogate for con-
cordance with guideline recommendations for pharmaco-
therapeutic interventions [6,8]. Two other areas of overlap
in guideline recommendations for asthma and COPD
included use of spirometry and influenza vaccination.
Spirometry was recommended by both guidelines for the
diagnosis and staging of disease and as a means to moni-
tor the disease progression and effect of treatment. Influ-
enza vaccination was recommended by both guidelines in
addition to the Center for Disease Control universal rec-
ommendation for influenza vaccinations for all patients
over the age of 65 [6,8,12].
The study was approved by the University of Wisconsin
institutional review board, which considered the study
exempt due to its use of publicly available data sets (45
CFR 46.101(b)(4)).
Table 2: Smoking History and Patterns in Health Care among Older Adults with Obstructive Respiratory Disease, 1992–2002
Older Adults with Obstructive 
Respiratory Disease
Older Adults with Obstructive Respiratory 
Disease & Treated with Pharmacotherapy
No 
Pharmacotherapy Pharmacotherapy * p-value
No short-acting  
inhaled
bronchodilator
Short-acting 
inhaled 
bronchodilator † p-value
Number of person-years 14,894 6,631 1,995 4,636
Annual use of health care, %
Spirometry examinations 0.08 0.24 <0.01 0.21 0.26 <0.01
Pulmonologist visits 0.08 0.27 <0.01 0.25 0.29 <0.01
Influenza vaccination 0.67 0.77 <0.01 0.73 0.79 <0.01
Emergency room visits 0.20 0.26 <0.01 0.26 0.25 0.59
Number of physician visits 8.94 10.95 <0.01 11.30 11.03 0.99
Number of days in hospital 2.76 4.37 <0.01 5.48 3.86 <0.01
Respiratory medications, %
Corticosteroid inhalers 0.23 0.35 <0.01
Xanthines 0.34 0.26 <0.01
Salmeterol 0.10 0.10 0.82
Leukotriene receptor 
antagonists
0.04 0.05 0.12
Oxygen 0.49 0.28 <0.01
Smoking History, %
None 0.35 0.24 <0.01 0.28 0.21 <0.01
Former Smoker 0.49 0.61 <0.01 0.58 0.62 <0.01
Current Smoker 0.16 0.15 0.02 0.14 0.17 <0.01
Influenza vaccination 0.67 0.77 <0.01 0.73 0.79 <0.01
* Respiratory treatments include oxygen, ipratropium (Atrovent®) inhaler, ipratropium-albuterol (Combivent®) inhaler, xanthines, leukotriene 
receptor antagonists, short-acting beta antagonist inhalers, salmeterol (Serevent®), and corticosteroid inhalers.
† Short-acting inhaled bronchodilators (metered dose inhalers and nebulizer solutions) include: beta-agonists ipratropium bromide (Atrovent®), and 
the combination of ipratropium bromide and albuterol (Combivent®) inhalers.
& All health care measures represent utilization over a calendar year.BMC Health Services Research 2008, 8:144 http://www.biomedcentral.com/1472-6963/8/144
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Results
Health status of older adults with COPD or Asthma
The estimated proportion of older adults with COPD or
asthma increased from 26% to 30% from 1992 to 2002
(Figure 1). The proportion of adults with only COPD
(18%) claims or only asthma (<1%) claims has remained
largely constant over the period 1992 through 2002. Over
the late 1990's, the proportion of older adults with both
asthma and COPD (5.6%) claims has increased, which
may suggest that more adults with asthma are being
treated as COPD patients. However, even with combining
the asthma-only and asthma and COPD claims, the prev-
alence of asthma in this older population is still much
lower than what would be expected in the general popu-
lation.
The proportion of older adults with self-reported COPD
or asthma and no claims has decreased. This last result,
when combined with the evidence of little change in the
relative prevalence of the respiratory diseases among older
adults, may suggest that in the late 1990's diagnosed cases
were more frequently treated, thereby rendering Medicare
claims.
Compared to those without COPD or asthma, older
adults with one of these conditions were more likely to
have an annual income less than $25,000, to be less edu-
cated and to be enrolled in Medicaid (Table 1). In addi-
tion to their lower socioeconomic status, their health
status was generally worse, including more chronic co-
morbidities, lower self-reported health status, and greater
limitations in activities of daily living. Fully 61% had
hypertension, 22% had cancer, 18% had diabetes and
13% arthritis. They were also 56% more likely to report
some difficulty walking two or three blocks compared to
those without COPD or asthma.
Patterns in health care
The following estimates in patterns of health care are
reported in terms of annual prevalence rates. Disparities
between ideal and real care exist across a range of indica-
tors promulgated by practice guidelines for COPD and
asthma. Each year about seventy percent of older adults
diagnosed with COPD or asthma did not receive any res-
piratory medications (Table 2). Slightly less than 22% of
older adults with COPD or asthma received short-acting
bronchodilator inhalers. A smaller minority (13%) of
older adults with either COPD or asthma received one or
more spirometry examinations during the year. Lastly,
72% of older adults with COPD or asthma received influ-
enza vaccinations recommended in guidelines.
Since there is no diagnostic severity index in the dataset to
evaluate the intensity of treatment provided, it is useful to
examine a subset of individuals whose care patterns sug-
gest moderate to more severe disease. We examined the
subset of older adults with COPD or asthma who had
received pharmacotherapy (Table 2). Consistent with the
possibility they had more disease severity, the data indi-
cate this group experienced more emergency room visits,
physician visits and days in the hospital than did their
counterparts who did not receive pharmacotherapy for
COPD or asthma.
Among this subset of older adults who received respira-
tory medications for COPD or asthma, we again see dis-
parities between practice guidelines and care in practice,
despite the fact they used significantly more preventive
and specialty services. (Table 2) Annually, thirty percent
did not receive any short-acting bronchodilator inhalers.
Although spirometry is important for the diagnosis and
grading of severity for both diseases, only about a quarter
of this subgroup received spirometry examinations annu-
ally. Influenza vaccinations are recommended each year
for all older adults, especially those with respiratory con-
ditions, but about one fifth of this subset did not receive
influenza vaccinations.
It is of interest to note, those who did receive short-acting
bronchodilator inhalers, as recommended in the existing
guidelines, had fewer days in the hospital. Adults treated
with short-acting bronchodilator inhalers were also more
likely to receive corticosteroid inhalers, and less likely to
receive xanthines and oxygen.
Smoking history and patterns in health care
A substantial portion (16%) of the older adults with
asthma or COPD continued to smoke, and the majority
(53%) were former smokers (Table 1). Compared to high
Prevalence of Obstructive Respiratory Diseases among  Older Adults, 1992–2002 Figure 1
Prevalence of Obstructive Respiratory Diseases among 
Older Adults, 1992–2002.
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school graduates with income over $25,000, current
smokers were more likely to represent persons with lower
incomes. Current and former smokers were more likely to
receive respiratory medications, particularly short-acting
bronchodilator inhalers, than adults who never smoked
(Table 2). This association might be related to disease
severity.
We next examined the association between smoking his-
tory and health care service use, as well as the relationship
between pharmacological treatments and health care serv-
ice use (Table 3). To do this, we estimated the odds and
rate of service use controlling for demographic, socioeco-
nomic, health, regional and time characteristics. Among
those with asthma or COPD, the odds of receiving a
spirometry examination were 24% less for a current
smoker (OR = 0.76) compared to a non-smoker or former
smoker. The rate of physician visits was also 22% less (RR
= 0.78). For each health service, current smokers were less
likely to receive care than adults who never smoked or
quit smoking. Overall, smokers are more likely to receive
pharmacotherapy, but if they continued smoking, they
were less likely to receive respiratory services such as
spirometry examinations and pulmonologist visits.
Discussion
Standards of care for patients with asthma and COPD
emphasize the role that bronchodilators play for control
of symptoms [6,8]. All persons with asthma should have
access to an inhaled beta-agonist for rescue from acute
symptoms [8]. Likewise, short-acting inhaled bronchodi-
lators continue to be recommended for symptomatic
treatment of mild, moderate and severe COPD [1,6]. Yet,
69% of this population with diagnosed obstructive respi-
ratory diseases received no respiratory medications at all
and 30% of those who did receive respiratory medications
did not receive any short-acting bronchodilator inhalers.
Half of the adults without inhaled bronchodilators
received oxygen therapy, perhaps representing persons
with severe COPD who may have benefited from use of
these agents [6]. Among those without inhaled bron-
chodilators, over one-third received xanthines. Long-act-
ing xanthines have benefit in the treatment of COPD and
may be added to other controller medications for moder-
ate or severe persistent asthma; however inhaled bron-
chodilators are recommended as the preferred agents in
both conditions due to reduced toxicity [6,8].
Both the asthma and COPD guidelines recommended use
of spirometry for diagnosis, grading severity and monitor-
ing progression of disease and response to treatment [6-
8], but it was used infrequently (13.3%) in this popula-
tion. Our low numbers of persons with asthma may be a
result of misdiagnosis as COPD because spirometry was
not often used.
Unlike the recommendations for bronchodilators and
spirometry, which are targeted for patients with COPD
and asthma, the recommendation for influenza vaccine
was universal for all older adults [12]. Despite this recom-
mendation, 28% of this high risk population did not
receive annual vaccinations.
Clearly, smoking is a grave problem among older adults
with COPD or asthma. Our finding that current smokers
receive less care than non-smokers or former smokers is
both troubling and intriguing. Further, that 16% who
continue is of concern.
In summary, this research found substantial gaps between
treatment guidelines and their implementation with
regard to drug therapy, spirometry, vaccinations and
smoking cessation in this population of vulnerable older
adults. These findings pose as many questions as they
answer. The overarching question is why clinical guide-
Table 3: Associations between Smoking Status and Patterns in Health Care among Older Adults with Obstructive Respiratory 
Disease, 1992–2002*
Any Spirometry 
examination&
Any 
Pulmonologist 
visits
Number of 
Physician Visits
Any Emergency 
room visits Any Hospital Days
Number of 
Hospital Days
OR (95% CI) † OR (95% CI) RR (95% CI) OR (95% CI) OR (95% CI) RR (95% CI)
Smoking history
None 1.00 1.00 1.00 1.00 1.00 1.00
Former smoker 1.00 (0.88–1.13) 1.12 (0.98–1.28) 0.97 (0.94–1.01) 1.06 (0.97–1.17) 1.10 (1.00–1.20) 1.04 (0.99–1.09)
Current smoker 0.76 (0.64–0.91) 0.76 (0.64–0.91) 0.78 (0.75–0.82) 0.87 (0.76–0.99) 0.81 (0.72–0.92) 0.91 (0.85–0.97)
* The base case represents a relatively health 70 year old male with obstructive respiratory disease, but no smoking history. This person resides in 
a northeastern city and has no drug coverage, over $25,000 in income, and a high school diploma.
† The logistic and negative binomial regression estimates are linearly adjusted for demographic, socioeconomic, health, region and time 
characteristics (See table 1). The number of hospital days is examined using a two-part model (i.e., logit and negative binomial) because of excess 
zeros in the count of hospital days.
& All health care measures represent utilization over a calendar year.BMC Health Services Research 2008, 8:144 http://www.biomedcentral.com/1472-6963/8/144
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lines for patients with obstructive pulmonary diseases are
not being followed for older patients with respect to med-
ication treatment, spirometry, vaccinations, and smoking
cessation. We believe that contributing factors could relate
to physicians, patients, and perhaps even the guidelines
themselves.
Studies demonstrate low physician adherence to clinical
guidelines [13,14]. Although internists in one study rec-
ognized the benefit of adhering to practice guidelines,
many were concerned about their effects on physician
autonomy and decision making, health care costs, and
satisfaction with clinical practice [15]. Others identified
lack of physician familiarity and, at times, agreement with
guidelines [16]. The 2001 guideline for COPD suggested
that some clinicians had a nihilistic approach to COPD
care because of the limited success of primary and second-
ary prevention, the notion that COPD was a self-inflicted
disease, and the paucity of good treatments available [6].
This line of reasoning suggests the value of interventions
which are both physician and health system focused.
Reminder systems, information resources for both provid-
ers and patients, as well as systematic feedback on the
quality of care provided through report cards and Health-
care Effectiveness Data and Information Set (HEDIS)
measures might also improve the delivery of care [17,18].
Although guidelines are distributed widely to physicians
in practice, they receive little education or practice imple-
menting the guidelines within the constraints of a busy
practice. Thus there is little opportunity to apply them
within the realities of more complicated patients with
other concerns.
Patient preference and choice may also account for devia-
tion from adherence to guidelines. Do some patients pre-
fer to focus more on treatment of other morbidities or on
other therapeutic interventions for COPD? Substantial lit-
erature suggests that the majority of patients with a serious
illness do want to play some shared role in therapeutic
decisions [19]. Further, the concept of evidence-based
medicine includes a role for patient preferences [20]. Let's
take one example with smokers to explore this possibility.
There may be a subset of smokers who experience such
nicotine addiction that quitting would be very difficult.
Recognizing this challenge, some physicians may have
come to respect their patients' choices to continue to
smoke. Another possibility is that a subset of physicians
has dismissed these patients because they failed to moti-
vate behavior change. A third possibility is that some of
these patients withdrew from care to avoid uncomfortable
encounters with physicians who urged smoking cessation.
Without further research on the actual encounters
between patients and providers, it is difficult to answer the
question about how much patient preference contributes
to the deviations documented in our analyses. There is a
need for more work, specifically on patient contributions
to this finding.
A caveat regarding the practice guidelines themselves is
that most guidelines come from research that does not
include older adults, calling into question the generaliza-
bility to this population [21]. Further, there are also ques-
tions as to whether the COPD guidelines in particular are
evidence based in terms of using outcomes that matter to
patients [22]. There is a need for more randomized studies
using patient-oriented outcomes in older adults with
COPD. Careful thought is needed to incorporate patient
quality of life priorities and therapeutic preferences in reg-
imen decisions. Both of these issues could lead to deci-
sions to deviate from conformity to guidelines.
Adherence to multiple guidelines for patients with comor-
bidities can have negative tradeoffs [21]. For example, in
our dataset, 61% of the patients have hypertension and
22% have cancer. Strict guideline adherence could poten-
tially result in overly complicated regimens with increased
risk of drug interactions and lower quality of life for peo-
ple with more than one condition. It may well be that
physicians are making tradeoffs with patients' comorbidi-
ties and competing priorities in mind. In addition to pro-
moting more discussion of how to handle these
situations, there is a glaring need to include more people
with multiple chronic conditions in clinical trials that ulti-
mately generate clinical practice guidelines.
Given that smoking cessation is the most important inter-
vention in the management of COPD [23], it is disturbing
that 16% in this data set continue to smoke. There is evi-
dence that practitioner concern about harming the doc-
tor-patient relationship may deter physicians from
making smoking cessation interventions [24]. However,
in at least one study when physicians are given written
suggestions and tear off sheets for patients, physicians
spoke with their patients about smoking cessation more
often. As noted by other researchers in this area, we need
more research on smoking cessation methods for older
adults with COPD, specifically to be sure that smoking
cessation guidelines are generalizable to this population
who may have more difficulty quitting [25].
Ultimately, we need more primary research with older
adults to complement our analysis of this unique, large
dataset. This group of older patients has not received the
intensity of research directed at younger populations with
asthma and COPD. As a result, clinicians and patients
alike are working with incomplete information needed to
address complex decision-making. Especially given a
movement to reward providers for adherence to practice
guidelines, it is vital that we revisit the care of older adults.BMC Health Services Research 2008, 8:144 http://www.biomedcentral.com/1472-6963/8/144
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Basic science is needed to sort out optimal treatment strat-
egies for patients who have comorbidities. More research
is also needed to evaluate the complex decision making by
patients and providers to understand the integration of
population-based guidelines into daily practice.
Limitations
The challenges involved in the study of older adults with
obstructive lung diseases reflect the concerns relating to
prevention, treatment and control of respiratory disease.
To identify those with obstructive lung diseases, we rely
on self-reported and claims-based indications of a clinical
diagnosis, instead of medical record data. Self-reported
measures may under-represent the prevalence of the dis-
ease due to recall bias, or may over-represent prevalence
due to a misunderstanding of the survey question. We rec-
ognize that some affirmative responses to questions like
"Did you have a flu shot for last winter?" may over-report
use due to social desirability bias, and that claims-based
measurement has also been shown to under-report the
prevalence of asthma, and to over-report the prevalence of
COPD [26]. Further measurement error may be related to
shifts in coding practices and raised awareness over time.
Although there are alternative measures for the identifica-
tion of disease and stage, these measures are not feasible
for a large epidemiologic study. We recognize that the self-
reported and claims-based measures of clinical diagnosis
have limitations, and have attempted to interpret the
results accordingly.
The sample excludes those who were not enrolled in the
traditional Medicare program for the full calendar year,
and is not generalizable to the entire community-dwelling
population of older adults. This exclusion was necessary
to control for observation bias in the claims and pre-
scribed medicine event data. For example, adults who
recently enrolled in Medicare have missing claims data
during the initial portion of the calendar year before their
enrollment. Similarly, those who drop out of traditional
Medicare, either through death, enrollment in Medicare
Plus Choice, or disenrollment from Medicare, also have
missing claims data.
Conclusion
Despite the proliferation of numerous guidelines for the
management of adults with obstructive respiratory dis-
eases, we found major deviations in use of these guide-
lines. Substantial proportions of older adults with COPD
or asthma do not receive a short-acting inhaled bron-
chodilators, infrequently used spirometry, fail to be vacci-
nated against influenza, and continue to smoke.
Disparities between actual care and care recommended in
guidelines suggest that more attention to older adults with
lung disease is needed in both research and treatment. The
special needs of older adults with comorbidities and long
histories of nicotine addiction deserve special attention in
guideline development and implementation. Reasons for
less than optimal care need to be further explored.
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